Inhibition of angiogenesis in human endothelial cell using VEGF specific nanobody
- 1 May 2015
- journal article
- Published by Elsevier in Molecular Immunology
- Vol. 65 (1) , 58-67
Abstract
No abstract availableKeywords
Funding Information
- Iranian Council of Stem Cell Technology (11/58 181)
This publication has 26 references indexed in Scilit:
- A nanobody directed to a functional epitope on VEGF, as a novel strategy for cancer treatmentBiochemical and Biophysical Research Communications, 2014
- Generation and characterization of a functional Nanobody against the vascular endothelial growth factor receptor-2; angiogenesis cell receptorMolecular Immunology, 2012
- Nanobodies, a promising tool for species-specific diagnosis of Taenia solium cysticercosisInternational Journal for Parasitology, 2009
- Targeted pharmacotherapy of retinal diseases with ranibizumabDrugs of Today, 2007
- Experimental therapy of African trypanosomiasis with a nanobody-conjugated human trypanolytic factorNature Medicine, 2006
- Vascular Endothelial Growth Factor: Basic Science and Clinical ProgressEndocrine Reviews, 2004
- Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancerNature Reviews Drug Discovery, 2004
- Vascular endothelial growth factor is efficiently synthesized in spite of low transfection efficiency of pSG5VEGF plasmids in vascular smooth muscle cellsVascular Medicine, 2000
- In Vitro Models of Angiogenesis: The use of MatrigelThe International Journal of Biological Markers, 1999
- Measurement of monoclonal antibody affinity by non-competitive enzyme immunoassayJournal of Immunological Methods, 1987